What Fairmount Funds Management LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1802528 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 2.5M |
| ±0% |
| $247.3M |
| 16.3% |
DMRADamora Therapeutics, Inc. | 8.7M | ±0% | $226.6M | 15% |
COGTCogent Biosciences, Inc. | 5.5M | ±0% | $213M | 14.1% |
JBIOJade Biosciences, Inc. | 4.6M | ±0% | $101.2M | 6.7% |
ELVNEnliven Therapeutics, Inc. | 1.9M | ±0% | $94.2M | 6.2% |
VRDNViridian Therapeutics, Inc. | 5.1M | +30.1% | $93.5M | 6.2% |
ZBIOZenas BioPharma, Inc. | 2.4M | ±0% | $59.9M | 4% |
CBIOCrescent Biopharma, Inc. | 2.7M | ±0% | $49.5M | 3.3% |
APGEApogee Therapeutics, Inc. | 298.6K | ±0% | $39.6M | 2.6% |
FTHFaeth Therapeutics, Inc. | 722K | New | $18.1M | 1.2% |
IKTInhibikase Therapeutics, Inc. | 8.6M | ±0% | $17.5M | 1.2% |
